Disease causing mutations in the TNF and TNFR superfamilies: Focus on molecular mechanisms driving disease

Grewal, 2009, Overview of TNF superfamily: a chest full of potential therapeutic targets, Adv. Exp. Med. Biol., 647, 1, 10.1007/978-0-387-89520-8_1 Locksley, 2001, The TNF and TNF receptor superfamilies: integrating mammalian biology, Cell, 104, 487, 10.1016/S0092-8674(01)00237-9 Aderka, 1996, The potential biological and clinical significance of the soluble tumor necrosis factor receptors, Cytokine Growth Factor Rev., 7, 231, 10.1016/S1359-6101(96)00026-3 Teachey, 2010, Somatic ALPS: a FAScinating condition, Blood, 115, 5125, 10.1182/blood-2010-04-278465 Worth, 2006, Autoimmune lymphoproliferative syndrome: molecular basis of disease and clinical phenotype, Br. J. Haematol., 133, 124, 10.1111/j.1365-2141.2006.05993.x Sneller, 1992, A novel lymphoproliferative/autoimmune syndrome resembling murine lpr/gld disease, J. Clin. Invest., 90, 334, 10.1172/JCI115867 Fisher, 1995, Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome, Cell, 81, 935, 10.1016/0092-8674(95)90013-6 Rieux-Laucat, 1995, Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity, Science, 268, 1347, 10.1126/science.7539157 Ramaswamy, 2009, Many checkpoints on the road to cell death: regulation of Fas-FasL interactions and Fas signaling in peripheral immune responses, Results Probl. Cell Differ., 49, 17, 10.1007/400_2008_24 Oliveira, 2010, Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from the 2009 NIH International Workshop, Blood, 116, e35, 10.1182/blood-2010-04-280347 van der Burg, 2000, Autoimmune lymphoproliferative syndrome (ALPS) in a child from consanguineous parents: a dominant or recessive disease?, Pediatric Res., 3, 336, 10.1203/00006450-200003000-00009 Bettinardi, 1997, Missense mutations in the Fas gene resulting in autoimmune lymphoproliferative syndrome: a molecular and immunological analysis, Blood, 89, 902, 10.1182/blood.V89.3.902 Martin, 1999, Defective CD95/APO-1/Fas signal complex formation in the human autoimmune lymphoproliferative syndrome, type Ia, Proc. Natl. Acad. Sci. U.S.A., 96, 4552, 10.1073/pnas.96.8.4552 Kasahara, 1998, Novel Fas (CD95/APO-1) mutations in infants with a lymphoproliferative disorder, Int. Immunol., 10, 195, 10.1093/intimm/10.2.195 Roesler, 2005, Haploinsufficiency, rather than the effect of an excessive production of soluble CD95 (CD95{Delta}TM), is the basis for ALPS Ia in a family with duplicated 3′ splice site AG in CD95 intron 5 on one allele, Blood, 106, 1652, 10.1182/blood-2004-08-3104 Vaishnaw, 1999, The molecular basis for apoptotic defects in patients with CD95 (Fas/Apo-1) mutations, J. Clin. Invest., 103, 355, 10.1172/JCI5121 Chan, 2007, Three is better than one: pre-ligand receptor assembly in the regulation of TNF receptor signaling, Cytokine, 37, 101, 10.1016/j.cyto.2007.03.005 Wang, 2010, The Fas-FADD death domain complex structure reveals the basis of DISC assembly and disease mutations, Nat. Struct. Mol. Biol., 17, 1324, 10.1038/nsmb.1920 Siegel, 2000, Fas preassociation required for apoptosis signaling and dominant inhibition by pathogenic mutations, Science, 288, 2354, 10.1126/science.288.5475.2354 Del-Rey, 2006, A homozygous Fas ligand gene mutation in a patient causes a new type of autoimmune lymphoproliferative syndrome, Blood, 108, 1306, 10.1182/blood-2006-04-015776 Wu, 1996, Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease, J. Clin. Invest., 98, 1107, 10.1172/JCI118892 Bi, 2007, Dominant inhibition of Fas ligand-mediated apoptosis due to a heterozygous mutation associated with autoimmune lymphoproliferative syndrome (ALPS) type Ib, BMC Med. Genet., 2, 41, 10.1186/1471-2350-8-41 Dowdell, 2010, Somatic FAS mutations are common in patients with genetically undefined autoimmune lymphoproliferative syndrome, Blood, 115, 5164, 10.1182/blood-2010-01-263145 Holzelova, 2004, Autoimmune lymphoproliferative syndrome with somatic Fas mutations, N. Engl. J. Med., 351, 1409, 10.1056/NEJMoa040036 Magerus-Chatinet, 2011, Onset of autoimmune lymphoproliferative syndrome (ALPS) in humans as a consequence of genetic defect accumulation, J. Clin. Invest., 121, 106, 10.1172/JCI43752 Williamson, 1982, Familial Hibernian fever, Q. J. Med., 51, 469 Kimberley, 2007, Falling into TRAPS–receptor misfolding in the TNF receptor 1-associated periodic fever syndrome, Arthritis Res. Ther., 9, 217, 10.1186/ar2197 McDermott, 1999, Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes, Cell, 97, 133, 10.1016/S0092-8674(00)80721-7 Wajant, 2003, Tumor necrosis factor signaling, Cell Death Differ., 10, 45, 10.1038/sj.cdd.4401189 Muppidi, 2004, Life and death decisions: secondary complexes and lipid rafts in TNF receptor family signal transduction, Immunity, 21, 461, 10.1016/j.immuni.2004.10.001 Hull, 2002, The TNF receptor-associated periodic syndrome (TRAPS): emerging concepts of an autoinflammatory disorder, Medicine (Baltimore), 81, 349, 10.1097/00005792-200209000-00002 Aksentijevich, 2001, The tumor-necrosis-factor receptor-associated periodic syndrome: new mutations in TNFRSF1A, ancestral origins, genotype-phenotype studies, and evidence for further genetic heterogeneity of periodic fevers, Am. J. Hum. Genet., 69, 301, 10.1086/321976 Tchernitchko, 2005, Unexpected high frequency of P46L TNFRSF1A allele in sub-Saharan West African populations, Eur. J. Hum. Genet., 13, 513, 10.1038/sj.ejhg.5201344 Nedjai, 2008, Abnormal tumor necrosis factor receptor I cell surface expression and NF-kappaB activation in tumor necrosis factor receptor-associated periodic syndrome, Arthritis Rheum., 58, 273, 10.1002/art.23123 Churchman, 2008, A novel TNFRSF1A splice mutation associated with increased nuclear factor kappaB (NF-kappaB) transcription factor activation in patients with tumour necrosis factor receptor associated periodic syndrome (TRAPS), Ann. Rheum. Dis., 67, 1589, 10.1136/ard.2007.078667 Siebert, 2005, Reduced tumor necrosis factor signaling in primary human fibroblasts containing a tumor necrosis factor receptor superfamily 1A mutant, Arthritis Rheum., 52, 1287, 10.1002/art.20955 Lobito, 2006, Abnormal disulfide-linked oligomerization results in ER retention and altered signaling by TNFR1 mutants in TNFR1-associated periodic fever syndrome (TRAPS), Blood, 108, 1320, 10.1182/blood-2005-11-006783 Siebert, 2005, Mutation of the extracellular domain of tumour necrosis factor receptor 1 causes reduced NF-kappaB activation due to decreased surface expression, FEBS Lett., 579, 5193, 10.1016/j.febslet.2005.08.037 Stjernberg-Salmela, 2004, A novel tumour necrosis factor receptor mutation in a Finnish family with periodic fever syndrome, Scand. J. Rheumatol., 33, 140, 10.1080/03009740310004892 Simon, 2010, Concerted action of wild-type and mutant TNF receptors enhances inflammation in TNF receptor 1-associated periodic fever syndrome, Proc. Natl. Acad. Sci. U.S.A., 107, 9801, 10.1073/pnas.0914118107 D’Osualdo, 2006, Neutrophils from patients with TNFRSF1A mutations display resistance to tumor necrosis factor-induced apoptosis: pathogenetic and clinical implications, Arthritis Rheum., 54, 998, 10.1002/art.21657 Huggins, 2004, Shedding of mutant tumor necrosis factor receptor superfamily 1A associated with tumor necrosis factor receptor-associated periodic syndrome: differences between cell types, Arthritis Rheum., 50, 2651, 10.1002/art.20380 Rebelo, 2006, Modeling of tumor necrosis factor receptor superfamily 1A mutants associated with tumor necrosis factor receptor-associated periodic syndrome indicates misfolding consistent with abnormal function, Arthritis Rheum., 54, 2674, 10.1002/art.21964 Todd, 2007, Mutant tumor necrosis factor receptor associated with tumor necrosis factor receptor-associated periodic syndrome is altered antigenically and is retained within patients’ leukocytes, Arthritis Rheum., 56, 2765, 10.1002/art.22740 Bulua, 2011, Mitochondrial reactive oxygen species promote production of proinflammatory cytokines and are elevated in TNFR1-associated periodic syndrome (TRAPS), J. Exp. Med., 208, 519, 10.1084/jem.20102049 Kamata, 2005, Reactive oxygen species promote TNFalpha-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases, Cell, 120, 649, 10.1016/j.cell.2004.12.041 Stojanov, 2008, Ann. Rheum. Dis., 67, 1292, 10.1136/ard.2007.079376 Gattorno, 2008, Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome, Arthritis Rheum., 58, 1516, 10.1002/art.23475 Salzer, 2005, Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency in humans, Nat. Genet., 37, 820, 10.1038/ng1600 Salzer, 2009, Relevance of biallelic versus monoallelic TNFRSF13B mutations in distinguishing disease-causing from risk-increasing TNFRSF13B variants in antibody deficiency syndromes, Blood, 113, 1967, 10.1182/blood-2008-02-141937 Bacchelli, 2007, Translational mini-review series on immunodeficiency: molecular defects in common variable immunodeficiency, Clin. Exp. Immunol., 149, 401, 10.1111/j.1365-2249.2007.03461.x Gross, 2000, TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease, Nature, 404, 995, 10.1038/35010115 Darce, 2007, Regulated expression of BAFF-binding receptors during human B cell differentiation, J. Immunol., 179, 7276, 10.4049/jimmunol.179.11.7276 Bossen, 2008, TACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL to support survival of activated B cells and plasmablasts, Blood, 111, 1004, 10.1182/blood-2007-09-110874 von Bulow, 1997, NF-AT activation induced by a CAML-interacting member of the tumor necrosis factor receptor superfamily, Science, 278, 138, 10.1126/science.278.5335.138 Yan, 2001, Activation and accumulation of B cells in TACI-deficient mice, Nat. Immunol., 2, 638, 10.1038/89790 Castigli, 2005, TACI and BAFF-R mediate isotype switching in B cells, J. Exp. Med., 201, 35, 10.1084/jem.20032000 Lee, 2010, The C104R mutant impairs the function of transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) through haploinsufficiency, J. Allergy Clin. Immunol., 126, 1234, 10.1016/j.jaci.2010.08.017 Garibyan, 2007, Dominant-negative effect of the heterozygous C104R TACI mutation in common variable immunodeficiency (CVID), J. Clin. Invest., 117, 1550, 10.1172/JCI31023 Dong, 2010, Phenotypic and clinical heterogeneity associated with monoallelic TNFRSF13B-A181E mutations in common variable immunodeficiency, Hum. Immunol., 71, 505, 10.1016/j.humimm.2010.02.002 He, 2010, The transmembrane activator TACI triggers immunoglobulin class switching by activating B cells through the adaptor MyD88, Nat. Immunol., 11, 836, 10.1038/ni.1914 Lee, 2009, The murine equivalent of the A181E TACI mutation associated with common variable immunodeficiency severely impairs B-cell function, Blood, 114, 2254, 10.1182/blood-2008-11-189720 Visinoni, 2009, Ectodermal dysplasias: clinical and molecular review, Am. J. Med. Genet. A., 149A, 1980, 10.1002/ajmg.a.32864 Zonana, 2000, A novel X-linked disorder of immune deficiency and hypohidrotic ectodermal dysplasia is allelic to incontinentia pigmenti and due to mutations in IKK-gamma (NEMO), Am. J. Hum. Genet., 67, 1555, 10.1086/316914 Doffinger, 2001, X-linked anhidrotic ectodermal dysplasia with immunodeficiency is caused by impaired NF-kappaB signaling, Nat. Genet., 27, 277, 10.1038/85837 Schneider, 2001, Mutations leading to X-linked hypohidrotic ectodermal dysplasia affect three major functional domains in the tumor necrosis factor family member ectodysplasin-A, J. Biol. Chem., 276, 18819, 10.1074/jbc.M101280200 Clauss, 2008, Dento-craniofacial phenotypes and underlying molecular mechanisms in hypohidrotic ectodermal dysplasia (HED): a review, J. Dent. Res., 87, 1089, 10.1177/154405910808701205 Yan, 2000, Two-amino acid molecular switch in an epithelial morphogen that regulates binding to two distinct receptors, Science, 290, 523, 10.1126/science.290.5491.523 Newton, 2004, Myodegeneration in EDA-A2 transgenic mice is prevented by XEDAR deficiency, Mol. Cell. Biol., 24, 1608, 10.1128/MCB.24.4.1608-1613.2004 Zhang, 2009, Reciprocal requirements for EDA/EDAR/NF-kappaB and Wnt/beta-catenin signaling pathways in hair follicle induction, Dev. Cell, 17, 49, 10.1016/j.devcel.2009.05.011 Vincent, 2001, Mutational spectrum of the ED1 gene in X-linked hypohidrotic ectodermal dysplasia, Eur. J. Hum. Genet., 9, 355, 10.1038/sj.ejhg.5200635 Chen, 2001, Mutations within a furin consensus sequence block proteolytic release of ectodysplasin-A and cause X-linked hypohidrotic ectodermal dysplasia, Proc. Natl. Acad. Sci. U.S.A., 98, 7218, 10.1073/pnas.131076098 Swee, 2009, Biological activity of ectodysplasin A is conditioned by its collagen and heparan sulfate proteoglycan-binding domains, J. Biol. Chem., 284, 27567, 10.1074/jbc.M109.042259 Clauss, 2010, X-linked and autosomal recessive hypohidrotic ectodermal dysplasia: genotypic-dental phenotypic findings from a retrospective study of 24 families, Clin. Genet., 78, 257, 10.1111/j.1399-0004.2010.01376.x Chassaing, 2006, Mutations in EDAR account for one-quarter of non-ED1-related hypohidrotic ectodermal dysplasia, Hum. Mutat., 27, 255, 10.1002/humu.20295 Chan, 2000, A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling, Science, 288, 2351, 10.1126/science.288.5475.2351 Clancy, 2005, Preligand assembly domain-mediated ligand-independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL-induced apoptosis, Proc. Natl. Acad. Sci. U.S.A., 102, 18099, 10.1073/pnas.0507329102 Chen, 2002, TNF-R1 signaling: a beautiful pathway, Science, 296, 1634, 10.1126/science.1071924 Micheau, 2003, Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes, Cell, 114, 181, 10.1016/S0092-8674(03)00521-X Emmerich, 2011, The linear ubiquitin chain assembly complex forms part of the TNF-R1 signaling complex and is required for effective TNF-induced gene induction and prevents TNF-induced apoptosis, Adv. Exp. Med. Biol., 691, 115, 10.1007/978-1-4419-6612-4_12 Chinnaiyan, 1995, FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis, Cell, 81, 505, 10.1016/0092-8674(95)90071-3 Ha, 2009, TRAF-mediated TNFR-family signaling, Curr. Protoc. Immunol., 11, 10.1002/0471142735.im1109ds87 Gardam, 2008, TRAF2 and TRAF3 signal adapters act cooperatively to control the maturation and survival signals delivered to B cells by the BAFF receptor, Immunity, 28, 391, 10.1016/j.immuni.2008.01.009 Haas, 2009, Recruitment of the linear ubiquitin chain assembly complex stabilizes the TNF-R1 signaling complex and is required for TNF-mediated gene induction, Mol. Cell, 36, 831, 10.1016/j.molcel.2009.10.013 Bodmer, 2002, The molecular architecture of the TNF superfamily, Trends Biochem. Sci., 27, 19, 10.1016/S0968-0004(01)01995-8 Chan, 2000, The pre-ligand binding assembly domain: a potential target of inhibition of tumour necrosis factor receptor function, Ann. Rheum. Dis., 59, i50, 10.1136/ard.59.suppl_1.i50 Deng, 2007, Tumor necrosis factor receptor pre-ligand assembly domain is an important therapeutic target in inflammatory arthritis, BioDrugs, 21, 23, 10.2165/00063030-200721010-00004 Arostegui, 2005, Etanercept plus colchicine treatment in a child with tumour necrosis factor receptor-associated periodic syndrome abolishes auto-inflammatory episodes without normalising the subclinical acute phase response, Eur. J. Pediatr., 164, 13, 10.1007/s00431-004-1563-1 Vaitla, 2011, Role of interleukin-6 (IL-6) in a patient with TRAPS revealed by treatment with tocilizumab (anti-IL-6 receptor monoclonal antibody), Arthritis Rheum., 63, 1151, 10.1002/art.30215 Teachey, 2010, Advances in the management and understanding of autoimmune lymphoproliferative syndrome (ALPS), Br. J. Haematol., 148, 205, 10.1111/j.1365-2141.2009.07991.x Teachey, 2006, Rapamycin improves lymphoproliferative disease in murine autoimmune lymphoproliferative syndrome (ALPS), Blood, 108, 1965, 10.1182/blood-2006-01-010124 Janic, 2009, Rapid regression of lymphadenopathy upon rapamycin treatment in a child with autoimmune lymphoproliferative syndrome, Pediatr. Blood Cancer, 53, 1117, 10.1002/pbc.22151 Teachey, 2009, Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome, Br. J. Haematol., 145, 101, 10.1111/j.1365-2141.2009.07595.x Castigli, 2005, TACI is mutant in common variable immunodeficiency and IgA deficiency, Nat. Genet., 37, 829, 10.1038/ng1601 Wang, 2005, Treatment and outcome of autoimmune hematologic disease in common variable immunodeficiency (CVID), J. Autoimmun., 25, 57, 10.1016/j.jaut.2005.04.006 Fisher, 2001, Nucleotide substitution in the ectodomain of trail receptor DR4 is associated with lung cancer and head and neck cancer, Clin. Cancer Res., 7, 1688 Park, 2001, Inactivating mutations of KILLER/DR5 gene in gastric cancers, Gastroenterology, 121, 1219, 10.1053/gast.2001.28663 Riches, 2008, Clinical and biochemical response of TNFRSF11A-mediated early-onset familial Paget disease to bisphosphonate therapy, Calcif. Tissue Int., 83, 272, 10.1007/s00223-008-9177-7 Othman, 2009, Mild autosomal recessive osteopetrosis: successful treatment with bone marrow transplant, Med. J. Malaysia, 64, 325 Cundy, 2005, Recombinant osteoprotegerin for juvenile Paget's disease, N. Engl. J. Med., 353, 918, 10.1056/NEJMoa050893 Winkelstein, 2003, The X-linked hyper-IgM syndrome: clinical and immunologic features of 79 patients, Medicine (Baltimore), 82, 373, 10.1097/01.md.0000100046.06009.b0